Kidney damage with normal or increased GFR Kidney damage with mild reduction in GFR
|
|
- Tiffany Clark
- 5 years ago
- Views:
Transcription
1 CHRONIC KIDNEY DISEASE Contents Stages of Chronic Kidney Disease Dosing adjustments Hyperphosphataemia management Secondary hyperparathyroidism Anaemias Hyperkalaemia Acidosis Hypertension STAGES OF CHRONIC KIDNEY DISEASE (CKD) Stage GFR/ Creatinine Clearance ml/min Description 1 >90 Kidney damage with normal or increased GFR Kidney damage with mild reduction in GFR Moderate damage with reduced GFR Severe reduction in GFR 5 <15 Renal Replacement / conservative management Review by: June 2017
2 DOSING ADJUSTMENTS IN CKD The level of renal function below which the dose of a drug must be reduced depends on the proportion of the drug eliminated by renal excretion and its toxicity Glomerular filtration rate (GRF) is a measure of the efficiency with which the kidneys can remove waste products such as creatinine and drugs from the bloodstream. egfr (reported on Meditech) is a useful indication in detecting CKD and allows timely and appropriate referral to renal specialists. If a patient s renal function is not changing rapidly, a population-based estimate of creatinine clearance can be derived from measurement of serum creatinine using the Cockcroft and Gault equation; Creatinine Clearance (ml/min) = F x (140-age)(weight in kg) Serum creatinine (micromol/l) where F = 1.23 (male) 1.04 (female) If the patient is overweight use the ideal body weight (IBW) in place of the actual body weight. Ideal body weight can be calculated as (kg): Males 50 + (2.3 x every inch over 5 ft) Females (2.3 x every inch over 5 ft) egfr estimates (ml/min/1.73m 2 ) are not the same as Cockcroft and Gault estimates of creatinine clearance (CrCl) (ml/min). egfr should not be used to adjust drug dosing. Most doses quoted in standard reference sources are based on Cockcroft and Gault equation and therefore this should remain the gold standard to estimate GFR when adjusting drug doses to an individual s renal function. Further help on drug dosing in CKD can be sought from ward pharmacist or the renal team.
3 MANAGEMENT OF HYPERPHOSPHATAEMIA Phosphate binders Phosphate binders are initiated in patients with serum phosphate > 1.4 mmol/l, despite dietary restriction. Compliance with low phosphate diet and phosphate binder therapy should be checked before increasing phosphate binder therapy. For patients who are hypocalcaemic or normocalcaemic (at lower end of scale) Calcium carbonate (Calcichew) 1.25g tablet (equivalent to 500mg elemental calcium per tablet) One tablet three times daily with meals. Increase to 2 tablets three times a day after 1 month if phosphate 1.4mmol/L (ensure patient remains normocalcaemic) Calcium acetate (Phosex) 1g tablet (equivalent to 250mg elemental calcium per tablet) One tablet three times daily with meals. Increase to 2 tablets three times a day after 1 month if phosphate 1.4mmol/L (ensure patient remains normocalcaemic) If calcium remains < 2.13 refer to Nephrology If phosphate remains 1.4mmol/L or if hypercalcaemic Sevelamer carbonate 800mg tablet One tablet three times daily with meals. Increase by 800mg three times a day after 1 month until phosphate 1.4mmol/L. Maximum 2400mg tds If phosphate remains 1.4mmol/L refer to Nephrologist of the week Aluminium hydroxide (Alucaps) 475mg capsules For initiation by Renal Team only 475mg three times daily with meals. Increase by 475mg tds until phosphate 1.4mmol/L. Maximum 1425mg tds
4 Lanthanum (Fosrenol) 500mg, 750mg, 1000mg chewable tablets For initiation by Renal Team only 750mg tablet three times daily with meals. Dosage should be titrated until phosphate 1.4mmol/L Precautions and adverse effects Serum corrected calcium and phosphate should be checked monthly and parathyroid hormone (PTH) every three months. For patients taking aluminium hydroxide, aluminium levels should be checked every three months. If hypercalcaemia develops, calcium based binders should be stopped and replaced where indicated by non-calcium containing binders (sevelamer). Review of vitamin D dosage may also be necessary. Phosphate binders must not be taken within 2 hours of oral iron supplements. Oral calcium may interfere with the absorption of bisphosphonates, ciprofloxacin, levothyroxine and tetracycline. These agents should be taken at least two hours before or four to six hours after calcium. Aluminium hydroxide may reduce the absorption of antibiotics (e.g.; cefaclor, quinolones, tetracyclines). Aluminium hydroxide is contra-indicated in patients with hypophosphataemia or porphyria. Accumulation in renal failure has been linked with neurotoxicity, osteomalacia and a reduced response to erythropoietin.
5 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM Vitamin D sterols and calcimimetric agents Alfacalcidol 250nanogram, 500nanogram, 1microgram capsules Initially 250nanograms daily. Adjust in increments of 250nanograms per day, initially at weekly intervals according to PTH and calcium levels. Once dose is stabilised review monthly. Calcitriol 250nanogram, 500nanogram capsules 1microgram/mL, 2microgram/mL injection For initiation by Renal Team only Initially 250nanograms daily. Adjust in increments of 250nanograms per day, initially at weekly intervals according to PTH and calcium levels. Once dose is stabilised review monthly. Cinacalcet For initiation by Renal Team only in line with NICE Guidance TA117 Initially 30mg daily. Titrate dose in 30mg increments at monthly intervals until PTH controlled. Check corrected calcium one week after each dose change as a reduction in PTH levels is associated with concomitant decrease in serum calcium levels. PTH levels should be checked at least 12 hours after dosing. Precautions and adverse effects PTH should only be measured routinely in patients with progressive CKD 3 and in stages 4 and 5. Only measure PTH in CKD stages 1 and 2 or non-progressive stage 3 if there is a clinical indication to do so (e.g., hypercalcaemia). PTH levels should be maintained between normal and twice the upper limit for CKD stage 4 and between two to four times the upper limit of normal for CKD stage 5. Treatment with vitamin D sterols should be initiated only in patients with serum levels of corrected calcium < 2.37mmol/L and serum phosphate <1.49mmol/L. During treatment with vitamin D sterols and cinacalcet, serum levels of calcium and phosphaste should be monitored monthly. Hypercalcaemia during treatment with vitamin D sterols can be corrected by stopping treatment until plasma calcium levels normalise (about 1 week). Plasma PTH levels should be monitored every 3 months for patients on Vitamin D sterols and monthly for patients on cinacalcet. Note 250 nanograms = 0.25 micrograms. Prescriptions for alfacalcidol should be written in terms of milligrams in line with the trusts medicines policy.
6 MANAGEMENT OF ANAEMIA Management of anaemia should be considered in people with anaemia of chronic kidney disease when their haemoglobin (Hb) level is less than or equal to 11g/dl.Treatment should maintain stable Hb between 11.5g/dl and 13g/dl. IRON-DEFICIENCY ANAEMIAS Oral Iron Use of modified release iron preparations is not recommended since these preparations release iron beyond the duodenum, an area where iron absorption is low. Ferrous sulphate 200mg tablets three times daily (equivalent to 65mg elemental iron per tablet) Precautions and adverse effects Absorption of oral iron may be reduced by calcium salts (commonly used as phosphate binding agents) and tetracyclines. Oral iron should not be administered concomitantly with parenteral iron. Oral iron reduces absorption of bisphosphonates, entacapone, levodopa, quinolones, tetracyclines, levothyroxine (give at least 2 hours apart) Adverse effects include gastro-intestinal irritation (nausea, constipation, diarrhoea) and stools may be discoloured (black). The incidence of side effects due to ferrous sulphate is no greater than with other iron salts when compared on the basis of equivalent amounts of elemental iron. Parenteral Iron Commence on advice of renal team in patients with ferritin < 100 micrograms/l after three months oral iron or <200 micrograms/l if GI intolerant to oral iron Iron Sucrose (Venofer) 100mg/5ml injection Please contact the renal team for further advice on dosing. Maximum dose 200mg. Risk of anaphylactic reaction. Infuse the first 25mg over 15 minutes. If no reaction increase rate to a maximum of 200mg/ hour Venofer may be available from pharmacy sterile production unit on request. Please contact the unit on Ext 5679
7 Precautions and adverse effects See above regarding risk of anaphylaxis and test dose. Facilities for cardiopulmonary resuscitation must be available whilst parenteral iron is administered. Target ferritin in renal patients is micrograms/l. Note ferritin is an acute phase reactant protein and may be elevated in the presence of infection and inflammation. Contra-indicated in patients with a history of asthma or other atopic allergy and in severe hepatic disease. ERYTHROPOETINS Darbepoetin For initiation by Renal Team only Epoetin alfa (Eprex) Starting dose of 0.45 microgram/kg (rounded to nearest syringe strength) once weekly by subcutaneous route. Monitor Hb monthly initially to maintain Hb g/dl. Once dose stable, follow up interval extended to 8-16 weeks By intravenous injection over 1 to 5 minutes (given during or at end of dialysis). Further dosing advice available from renal unit For initiation by Renal Team only for patients on haemodialysis unit By intravenous injection over 1 to 5 minutes (given during or at end of dialysis). Further dosing advice available from renal unit Darbepoetin is a hyperglycosylated derivative of epoetin. It has a longer half life and can be administered less frequently than epoetin. Other factors which contribute to the anaemia of chronic kidney failure such as iron or folate deficiency should be corrected before treatment and monitored during therapy. Serum ferritin should be >200mcg/L before commencing erythropoietin. Supplemental iron may improve the response in resistant patients. Aluminium toxicity, concurrent infection or other inflammatory disease can impair the response to erythropoietin. Precautions and adverse effects CSM advice; There have been rare reports of pure red cell aplasia in patients treated with epoetin alfa. The CSM has advised that in patients that fail to respond to epoetin alfa therapy, with a diagnosis of pure red cell aplasia, treatment with epoetin alfa must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should not be switched to another form of erythropoietin. Contraindicated in uncontrolled hypertension or patients unable to receive thromboprophylaxis.
8 Monitor haemoglobin, blood pressure and potassium (risk of hyperkalaemia). If diastolic blood pressure >100mmHg or systolic blood pressure >200mmHg after 3 consecutive readings in a week, discontinue erythropoietin therapy. Patients receiving ciclosporin or tacrolimus should have their levels monitored. Adverse effects include hypertensive crisis with encephalopathy-like symptoms and seizures, allergic reactions and thrombotic events.
9 MANAGEMENT OF HYPERKALAEMIA IN PATIENTS WITH CKD Guidelines for the treatment of hyperkalaemia (See also section in nutrition & blood) Checklist; Is the potassium result a true value? Could the blood have haemolysed? If patient is a dialysis patient, is this a pre or immediately post dialysis reading? Pre-dialysis readings are usually high & immediate post dialysis samples are low until the patient re-equilibrates (up to 4 hours post dialysis) Is the patient due to have imminent dialysis? If the potassium level is not life threatening and haemodialysis is planned within 12 hours no action may be required please contact the renal department for further advice Is hyperkalaemia acute or chronic? Does the patient often have high or low potassium? Is there a drug cause e.g.; ACE inhibitor, ARB, NSAIDs, amiloride, spironolactone? Can the drug be stopped safely? Immediate treatments Treatment should be given immediately if potassium is greater than 6.5mmol/L especially if there are ECG changes or neuromuscular symptoms. 1. Intravenous calcium Give 10mL intravenous calcium gluconate 10% (2.25mmol Ca 2+ in 10mL) over 5 minutes when the ECG changes include widening of the QRS complexes with slurring of the ST segments. Although this is the standard dose of calcium gluconate, more should be given without hesitation in resistant cases until the ECG returns to normal. A dose of 30mL is commonly required, although up to 90mL can be given in rare cases. Calcium chloride (10mmol in 10mL) can be given instead of calcium gluconate, however care is required with repeated dosing due to the greater concentration of calcium in the chloride preparation. 2. Insulin and glucose Give 10 to 15 units of Actrapid insulin and 50mL glucose 50% over 20 minutes into a large vein. Insulin will promote the transport of extracellular potassium into the cells. Glucose covers the insulin-induced hypoglycaemia. Blood glucose should be checked 30 minutes after treatment and then hourly for up to 6 hours to avoid hypoglycaemia. Plasma potassium will decrease by about 1mmol/L within 30 minutes and the effect should last for 1 or 2 hours.
10 3. Nebulised salbutamol Nebulising 2.5 to 10mg salbutamol will reduce serum potassium by 0.5 to 1.5mmol/L. Use lower doses in patients with ischaemic heart disease. Caution as sympathetic activity will be increased causing tachycardia arrrhythmias and fine tremors 4. Sodium bicarbonate Raising the systemic ph results in hydrogen ion release from the cells and moves potassium into cells. There is also a direct effect independent of ph. Effects begin within minutes and last for 6-8 hours. Give sodium bicarbonate 1000mg three times a day orally or 500mls 1.26% IV (via central or peripheral line) over 6 hours. Caution in fluid restricted patients as can cause salt and water overload Maintenance treatments 1. Calcium Resonium Ion exchange resin exchanges calcium for potassium in the gut. More useful in chronic rather than acute hyperkalaemia as effects begin in 2-12 hours and last for hours after stopping. Give calcium resonium 15g orally in water three to four times a day. Caution; can cause severe constipation, therefore always prescribe laxatives concomitantly. If the patient remains hyperkalaemic and unresponsive to treatment, call for consultant help. SODIUM BICARBONATE If bicarbonate <25mmol, commence Sodium Bicarbonate capsule 500mg three times daily. Increase according to bicarbonate levels and tolerability.
11 MANAGEMENT OF HYPERTENSION IN CKD Blood pressure should be lowered to <130/80mmHg Treatment of hypertension affords the dual benefit of slowing the rate of progression of CKD and reducing cardiovascular risk in patients with CKD. Angiotensin converting enzyme (ACE) inhibitors should be considered as the agents of first choice in the management of hypertension in patients with progressive renal disease. ACE inhibitors or Angiotensin Receptor Blocker (ARB) treatment should form part of the antihypertensive therapy of patients with CKD and urinary protein excretion of >1g/day (urine protein:creatinine ratio of >100mg/mmol or >1mg/mg) unless there is a specific contraindication. Treatment with ACE inhibitors- commence if serum potassium within normal range Lisinopril Start at 2.5mg daily. Titrate to 20mg daily over 4 weeks. Dosage can be doubled weekly. At each dose change check U/Es to ensure renal stability and absence of hyperkalaemia. If no dose change, check U/Es at 1 week, 1 month, 3 months, 6 months and annually. Begin treatment with ARB if patient unable to tolerate ACE inhibitor due to ACE induced cough Losartan Start at 50mg daily (25mg daily in intravascular volume depletion or patients >75. Increase to 100mg daily if tolerated. Irbesartan Start at 150mg daily. Increase to 300mg daily if tolerated. In haemodialysis of elderly consider initial dose of 75mg daily. Treatment with ACE inhibitor or ARB should be continued if a GFR decline over 4 months is <30% from baseline and serum potassium is 5.5mmol/L Dual blockade with a combination of ACE inhibitor or ARB should usually only be initiated under specialist supervision. For patients unable to tolerate ACE inhibitors due to cough, dual blockade using an ARB plus the direct renin inhibitor aliskiren may be considered. This combination should be initiated by consultant nephrologists only.
12 If on maximum dose of ACE inhibitor or ARB and BP> 130/80mmHg, start; Furosemide Start at 20mg each morning and titrate upwards according to response. Monitor U/Es at one to two weekly intervals. Note; larger doses of diuretics may be indicated in CKD patients. Doses up to 500mg daily are sometimes used in management of oedema. or for patients with CKD 1-3 Bendrofluazide 2.5mg daily If BP still above 130/80mmHg add; Amlodipine Start at 5mg daily and increase to 10mg daily if still above target value two weeks after starting medication or if proteinuric & unable to tolerate ACE inhibitor or ARB due to hyperkalaemia start; Diltiazem MR Start at 200mg daily and increase to max 300mg daily if still above target value two weeks after starting medication. Heart rate should be monitored and if falls below 50bpm dose should not be increased. Note; Diltiazem is used in place of amlodipine, NOT in addition to. Diltiazem should not be given in combination with beta blockers due to increased risk of AV block and bradycardia. Different versions of modified release preparations may not have the same clinical effect. To avoid confusion between different formulations, prescribers should specify the brand to be dispensed. If BP still above 130/80mmHg add; Doxazosin (standard release) Start at 1mg daily, increase after 1-2 weeks to 2mg daily, and thereafter to 4mg daily, if necessary to a maximum 16mg daily if still above target value. If BP remains above 130/80mmHg despite use of the above agents, please consider referral to Nephrology
Clinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationMedicines Formulary Blood and electrolyte disorders, and vitamin deficiencies
Medicines Formulary Blood and electrolyte disorders, and vitamin deficiencies Contents: Blood disorders 1 1. Anaemia 2 A. Non-renal patients 2 B. Patients with chronic kidney disease under the care of
More informationNOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT Phosphate Binders for the Treatment of Hyperphosphataemia in adults with Chronic Kidney Disease OBJECTIVES To outline referral
More informationMedicines Formulary Blood and electrolyte disorders, and vitamin deficiencies
Medicines Formulary Blood and electrolyte disorders, and vitamin deficiencies Contents: Blood disorders 1 1. Anaemia 2 A. Non-renal patients 2 B. Patients with chronic kidney disease under the care of
More informationNutrition 1 1. Total parenteral nutrition (TPN) 2 2. Enteral nutrition 2 3. Coeliac disease 3
Medicines Formulary Nutrition, blood and electrolyte disorders Contents: Nutrition 1 1. Total parenteral nutrition (TPN) 2 2. Enteral nutrition 2 3. Coeliac disease 3 Blood disorders 3 4. Anaemia 3 A.
More informationMedicines for anaemia and mineral bone disease
Patient Information: Medicines NHS Logo here Medicines for anaemia and mineral bone disease Health & care information you can trust The Information Standard Certified Member Working together for better
More informationKent Kidney Care Centre: Medicines prescribed for people with chronic kidney disease
Kent Kidney Care Centre: Medicines prescribed for people with chronic kidney disease Information for patients The following pages offer you information on some of the medicines that you may need. It is
More informationCOMMON MEDICINES USED IN CKD CHRONIC KIDNEY DISEASE
CHRONIC KIDNEY DISEASE 1 This information is intended to help you understand why you need to take your medicines. There are multiple medicines that are used to control the symptoms related to CKD. You
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationELECTROLYTES RENAL SHO TEACHING
ELECTROLYTES RENAL SHO TEACHING Metabolic Alkalosis 2 factors are responsible for generation and maintenance of metabolic alkalosis this includes a process that raises serum bicarbonate and a process that
More informationChronic Kidney Disease in Primary Care
Clinical Stream Chronic Kidney Disease in Primary Care Dr Gerald Waters Dr Gerald Waters Renal Physician Chronic Kidney Disease Chronic Kidney Disease Normal functions of Kidneys Management of CKD Drugs
More informationReport generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation Abidec Adcal-D3 Addiphos Additrace 9.6 Vitamins->9.6.7
More informationBNF 9: Blood and Nutrition
FORMULARY CHOICE RESTRICTED 1 Blood and Blood-Forming Organs 1.1 Anaemias Epoetins Epoetinalfa pre-filled (Eprex ) 1,000unit 2,000unit 3,000unit 4,000unit 5,000unit 6,000unit 8,000unit 10,000unit 20,000unit
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationPatient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton
Rationale for Initiation, Continuation and Discontinuation (RICaD) Sacubitril/Valsartan (Entresto) For the treatment of symptomatic heart failure with reduced ejection fraction (NICE TA388) This document
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationCommon Medication for People Receiving Haemodialysis
Common Medication for People Receiving Haemodialysis Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS PRODUCT SUMMARY 1. NAME OF THE MEDICINAL PRODUCT Sterile Potassium Chloride Concentrate 15%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 15% of Potassium Chloride in
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDiabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy
Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in
More informationGUIDELINES FOR MAINTAINING SERUM CALCIUM FOLLOWING PARATHYROIDECTOMY IN PATIENTS WITH CHRONIC KIDNEY DISEASE RRCV CMG Renal and Transplant Service
GUIDELINES FOR MAINTAINING SERUM CALCIUM FOLLOWING PARATHYROIDECTOMY IN PATIENTS WITH CHRONIC KIDNEY DISEASE RRCV CMG Renal and Transplant Service 1. Introduction Secondary hyperparathyroidism is an important
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationDisclosures. Topics. Staging and GFR. K-DOQI Staging of Chronic Kidney Disease. Definition of Chronic Kidney Disease. Chronic Kidney Disease
Disclosures Chronic Kidney Disease Consultant: Baxter Healthcare J. Kevin Tucker, M.D. Brigham and Women s Hospital Massachusetts General Hospital Topics Staging of chronic kidney disease (CKD) How to
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationTumour Lysis Syndrome (TLS)
(TLS) Overview: Tumour lysis syndrome refers to a number of metabolic disturbances (hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypocalcaemia) that occur as the result of rapid cell lysis. This
More informationChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist
More informationIntroduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team
Introduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team Drugs play a major role in both treating and causing renal disease Doses of some drugs need to be
More informationPolicy for the use of intravenous Iron Dextran (CosmoFer )
Policy for the use of intravenous Iron Dextran (CosmoFer ) Sharepoint Location Clinical Policies and Guidelines Sharepoint Index Directory General Policies and Guidelines Sub Area Haematology and Blood
More informationSwindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationCG1339. Version: Renal Services Group. Approving forum (QIPS or equivalent):
University Hospitals Coventry & Warwickshire NHS Trust Clinical Guideline (full) CHRONIC KIDNEY DISEASE (CKD) NUTRITIONAL RECOMMENDATIONS FOR PERITONEAL DIALYSIS E-Library Reference CG1339 Version: Approving
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationCLINICAL GUIDELINES ID TAG
CLINICAL GUIDELINES ID TAG Title: Treatment of Hypomagnesaemia in adults Author: Speciality / Division: Directorate: Dr Peter Sharpe, Dr Neal Morgan, Jillian Redpath Chemical Pathology/Nephrology/Pharmacy
More informationChronic Kidney Disease
Chronic Kidney Disease Presence of kidney damage or decreased kidney function for three or more months, - necessary to distinguish CKD from acute kidney disease. Ascertained either by kidney biopsy or
More informationCAUTION: You must refer to the intranet for the most recent version of this procedural document.
Procedure for the use of Intravenous Iron Dextran (CosmoFer ) Sharepoint Location Sharepoint Index Directory Clinical Policies and Guidelines General Policies and Guidelines/ Haematology And blood transfusion
More informationAcute Renal Failure. Dr Kawa Ahmad
62 Acute Renal Failure Dr Kawa Ahmad Acute Renal Failure It is characterised by an abrupt reduction (usually within a 48- h period) in kidney function. This results in an accumulation of nitrogenous waste
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationMedical therapy of AKI complications. Refik Gökmen AKI Academy 18 October 2014
Medical therapy of AKI complications Refik Gökmen AKI Academy 18 October 2014 Medical therapy of AKI complications Hyperkalaemia Volume status, fluid therapy Acidosis Calcium & phosphate Bleeding risk
More informationPHARMACOLOGY AND PHARMACOKINETICS
DRUG GUIDELINE Insulin, human neutral (Actrapid ) Intravenous Infusion for SCOPE (Area): FOR USE IN: Critical Care Unit, Emergency Department and Operating Suite EXCLUSIONS: Paediatrics (seek Paediatrician
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationPaediatric Nephrology Date of submission March 2014
Hyperkalaemia Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline for the assessment and management of hyperkalaemia
More informationROYAL WOLVERHAMPTON HOSPITALS NHS TRUST
ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST SHARED CARE PROTOCOL FOR ERYTHROPOIETIN USE 2016 New Cross Hospital Dr J Odum Dr P B Rylance Dr P Carmichael Dr S Acton Dr B Ramakrishna Walsall Manor Hospital Dr
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationChronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
This is an official Northern Trust policy and should not be edited in any way Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Reference Number: NHSCT/12/553 Target
More informationPRODUCT INFORMATION RESONIUM A. Na m
PRODUCT INFORMATION RESONIUM A NAME OF THE MEDICINE Non-proprietary Name Sodium polystyrene sulfonate Chemical Structure CH - 2 CH SO 3 Na + n CAS Number 28210-41-5 [9003-59-2] CH 2 CH SO - 3 m DESCRIPTION
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationGUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE
GUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if
More informationReport generated from MPH Formulary provided by FormularyComplete ( Accessed Formulary Status. TA Number.
Report generated from MPH provided by Complete (www.pharmpress.com). Accessed 18 01 2016 Title Status Section TA Number TA Link Colecalciferol No UK PL 9.6 Vitamins->9.6.4 Vitamin D->COLECALCIFEROL Colecalciferol
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationVolume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)
Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical
More informationGuidelines for the Prescribing of Sacubitril / Valsartan
Hull & East Riding Prescribing Committee Guidelines for the Prescribing of Sacubitril / Valsartan 1. BACKGROUND Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor, including both a neprilysin
More informationThe P&T Committee Lisinopril (Qbrelis )
Situation Background Assessment The P&T Committee Lisinopril (Qbrelis ) Qbrelis, 1 mg/ml lisinopril oral solution, has recently become an FDA- approved formulation. Current practice at UK Chandler Medical
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin zeta, 1000 IU/0.3ml, 2000 IU/0.6ml, 3000 IU/0.9ml, 4000 IU/0.4ml, 5000 IU/0.5ml, 6000 IU/0.6ml, 8000 IU/0.8ml, 10,000 IU/1.0ml, 20,000 IU/0.5ml, 30,000 IU/0.75ml and
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationGlucophage XR is contra-indicated during breast-feeding.
Name GLUCOPHAGE XR 1000 mg Prolonged release tablets Active ingredient Metformin hydrochloride Composition Each Glucophage XR 1000 mg prolonged release tablet contains as active ingredient 1000 mg metformin
More informationPOTASSIUM DIHYDROGEN PHOSPHATE 13.6% CONCENTRATED INJECTION
POTASSIUM DIHYDROGEN PHOSPHATE 13.6% CONCENTRATED INJECTION NAME OF THE MEDICINE Potassium Dihydrogen Phosphate Synonyms: potassium biphosphate, potassium acid phosphate, monopotassium phosphate, or monoibasic
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationCisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck
Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Indication: 1) Concomitant chemo-radiotherapy for locally advanced squamous cell carcinoma head and neck 2) Post-operative
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationNottingham Renal and Transplant Unit
Nottingham Renal and Transplant Unit Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationMr PA. Clinical assessment of hydration. Poor urine output Sunken eyes Moistness of mucosa Cool peripheries Reduction in weight Postural hypotension
X Anthony Warrens Mr PA 54 years old Previously well Went to Thailand Developed serious diarrhoea and vomiting two days before coming home 24 hours after return, still unwell GP found: urea 24 mmol/l creatinine
More informationHello, and thank you for joining us for this presentation on novel approaches to understanding risks and treatment of hyperkalemia.
Hello, and thank you for joining us for this presentation on novel approaches to understanding risks and treatment of hyperkalemia. PP-US-DSE-00032. 2015 Relypsa, Inc. All rights reserved. Relypsa and
More informationGreater Manchester Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
Greater Manchester Guidelines on the Management of (CKD-MBD) Classification: Clinical Guideline Lead Author: Smeeta Sinha, Consultant Nephrologist Additional author(s): Elizabeth Lamerton, Renal Pharmacist
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationDBL MAGNESIUM SULFATE CONCENTRATED INJECTION
DBL MAGNESIUM SULFATE CONCENTRATED INJECTION NAME OF MEDICINE Magnesium Sulfate BP DESCRIPTION DBL Magnesium Sulfate Concentrated Injection is a clear, colourless, sterile solution. Each ampoule contains
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationSUMMARY OF PRODUCT CHARACTERISTICS. One chewable tablet contains 1250 mg calcium carbonate (equivalent to 500 mg calcium).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT [XXX] 500 mg chewable tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One chewable tablet contains 1250 mg calcium carbonate (equivalent
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationShared Care Guideline Metolazone for fluid management in CKD (Adults)
Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Calcium Sandoz 500 mg, effervescent tablets Calcium Sandoz 1000 mg, effervescent tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationNorthern Treatment Advisory Group
Northern Treatment Advisory Group Ferric Maltol (Feraccru ) for the treatment of iron deficiency Lead author: Daniel Hill Regional Drug & Therapeutics Centre (Newcastle) September 2018 2018 Summary Iron
More informationSupplement: Summary of Recommendation Statements CHAPTER 1: DEFINITION AND CLASSIFICATION OF CKD
Supplement: Summary of Recommendation Statements CHAPTER 1: DEFINITION AND CLASSIFICATION OF CKD 1.1 DEFINITION OF CKD 1.1.1: CKD is defined as abnormalities of kidney structure or function, present for
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationProfessor Suetonia Palmer
Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS
More informationChronic Kidney Disease (CKD) and egfr: Decision and Dilemma. Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree
Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree Topics CKD background egfr background Patient with egfr Referral Guidelines
More informationStart. What is the serum phosphate concentration? Moderate Hypophosphataemia mmol/l. Replace using oral. phosphate. (See section 3.
CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPOPHOSPHATAEMIA IN ADULTS Summary. Key: General Notes GP/SWASFT ED/MAU/SRU/Acute GP/Amb-Care In-patient wards Start What is the serum concentration? Mild Hypophosphataemia
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationGuidelines on Anaemia Management in Patients with Chronic Kidney Disease (CKD)
Guidelines on Anaemia Management in Patients with Chronic Kidney Disease (CKD) This guideline is for use in adult patients with an estimated Glomerular Filtration Rate (egfr) of less than 60ml/min/1.73m
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 2-year surveillance (2017) Chronic kidney disease: managing anaemia (2015) NICE guideline NG8 Appendix A3: Summary of new evidence from surveillance Diagnostic
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationTacrolimus (Adoport, Prograf, Modigraf or Advagraf )
Shared Care Guideline DRUG: Tacrolimus (Adoport, Prograf, Modigraf or Advagraf ) for Renal Transplant (Adults) Introduction: Indication: Prophylaxis of transplant rejection in kidney recipients Tacrolimus
More informationKidney Disease. Chronic kidney disease (CKD) requiring dialysis. The F.P. s Role in the Management of Chronic. Stages
Focus on CME at McMaster University The F.P. s Role in the Management of Chronic Kidney Disease By David N. Churchill, MD, FRCPC, FACP Presented at McMaster University CME Half-Day in Nephrology for Family
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationInvestigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis
Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis Tutorial for Specialist Portfolio Biomedical Scientists 03/02/2014 Dr Petros Kampanis Clinical Scientist 1. Calcium Most abundant
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. SODIPHOS 22mEq / 10ml Concentrate for solution for infusion. Disodium phosphate dihydrate
PACKAGE LEAFLET: INFORMATION FOR THE USER SODIPHOS 22mEq / 10ml Concentrate for solution for infusion Disodium phosphate dihydrate Read all of this leaflet carefully before you start using this medicine.
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationPP-US-DSE Relypsa, Inc. All rights reserved. Relypsa and the Relypsa logo are trademarks of Relypsa, Inc.
1 2 There are 4 main objectives that I d like to cover with you today: First, to review the definition, prevalence, and risk of hyperkalemia in certain populations Second, to review why RAASi are recommended
More information